Esophageal Neoplasms

• 

  Subject Areas on Research

  • "Early" thoracic duct ligation for chylothorax after esophagectomy means "now". 
  • A NEIL1 single nucleotide polymorphism (rs4462560) predicts the risk of radiation-induced toxicities in esophageal cancer patients treated with definitive radiotherapy. 
  • A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. 
  • A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. 
  • A Rare Cause of Confluent Abnormal Esophageal Mucosa. 
  • A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress. 
  • A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II trial for minimally invasive esophagectomy. 
  • A prospective study of esophageal squamous cell carcinoma in achalasia. 
  • A unique tripartite collision tumor of the esophagus: A case report. 
  • ACR Appropriateness Criteria® Staging and Follow-Up of Esophageal Cancer. 
  • Ablative therapies for Barrett's esophagus. 
  • Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma. 
  • Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. 
  • Adult respiratory distress syndrome after limited thoracic radiotherapy. 
  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. 
  • Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck. 
  • Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking. 
  • Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations. 
  • Barrett's esophagus and esophageal cancer: Links to microbes and the microbiome. 
  • Barrett's esophagus in 2008: an update. 
  • Bilateral vocal cord paralysis following stent placement for proximal esophageal stricture. 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • CT of fundoplication. 
  • Carcinoma of the esophagus with mixed basaloid squamous and glandular differentiation: a distinct histological presentation. 
  • Carcinomas of the hypopharynx and cervical esophagus: A systematic review and quality of evidence assessment. 
  • Carcinosarcomas of the esophagus: systematic review of a rare nosologic entity. 
  • Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 
  • Changing the Rules of Resectability of T4b Esophageal Cancer Invading Aorta. 
  • Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. 
  • Clinical applications of PET in oncology. 
  • Combination chemotherapy with cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (CDDP) for squamous cancers of the upper aerodigestive tract. 
  • Comment on "Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database". 
  • Comment on "Direct Oral Feeding After Minimally Invasive Esophagectomy (NUTRIENT II trial): An International, Multicenter, Open-label Randomized Controlled Trial". 
  • Comment on "Early Feeding After Esophagectomy: Show Must Go On". 
  • Comment on "The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study". 
  • Commentary: Induction immunotherapy for esophageal cancer: A safe start. 
  • Commentary: Minimally invasive esophagectomy: Steady progress. 
  • Commentary: Octogenarians and Esophageal Cancer, Are We Afraid to Treat, or Are We Missing Information? 
  • Commentary: You can't hit what you can't see: Esophageal adenocarcinoma with signet ring cells. 
  • Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis. 
  • Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation. 
  • Computed tomography of the gastroesophageal junction: value of the left lateral decubitus view. 
  • Concentration of Tc-99m methylenediphosphonate in hepatic metastases from squamous cell carcinoma. 
  • Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. 
  • Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. 
  • Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. 
  • Current and future cancer staging after neoadjuvant treatment for solid tumors. 
  • DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 
  • Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. 
  • Depth of Muscularis Propria Invasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma. 
  • Detection of dysplasia in Barrett's esophagus with in vivo depth-resolved nuclear morphology measurements. 
  • Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. 
  • Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. 
  • Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. 
  • Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. 
  • Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. 
  • Drivers of Esophageal Adenocarcinoma and Opportunities for Cancer Interception. 
  • Ductal metaplasia in oesophageal submucosal glands is associated with inflammation and oesophageal adenocarcinoma. 
  • EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance? 
  • Early results with combined modality therapy for carcinoma of the esophagus. 
  • Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma. 
  • Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat. 
  • Efficacy of cryotherapy as first line therapy in patients with Barrett's neoplasia: a systematic review and pooled analysis. 
  • Endoscopic approaches for early-stage esophageal cancer: current options. 
  • Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. 
  • Endoscopic ultrasonography in the diagnosis and staging of neoplasms of the head and neck. 
  • Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. 
  • Esophageal OCT Imaging Using a Paddle Probe Externally Attached to Endoscope. 
  • Esophageal adenocarcinoma in a patient with surgically treated achalasia. 
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. 
  • Esophageal and esophagogastric junction cancers, version 1.2015. 
  • Esophageal and esophagogastric junction cancers. 
  • Esophageal cancer staging by CT: long-term follow-up study. 
  • Esophageal cancer. 
  • Esophageal cancer. Clinical practice guidelines in oncology. 
  • Esophageal granular cell tumor and eosinophils: a multicenter experience. 
  • Esophageal submucosal glands as a potential source of subsquamous intestinal metaplasia in Barrett's esophagus. 
  • Esophageal-subarachnoid fistula: a case of spontaneous tension pneumocephalus in the setting of esophageal cancer. 
  • Esophagectomy outcomes at low-volume hospitals: the association between systems characteristics and mortality. 
  • Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model. 
  • Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. 
  • Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. 
  • Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. 
  • Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus. 
  • Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype. 
  • Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). 
  • Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Further justification for development of non-invasive thermometry. 
  • Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. 
  • Genetic variants in miR-196a2 and miR-499 are associated with susceptibility to esophageal squamous cell carcinoma in Chinese Han population. 
  • Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. 
  • Genome-wide association study identifies three susceptibility loci for laryngeal squamous cell carcinoma in the Chinese population. 
  • Giant esophageal lipoma: endoscopic resection. 
  • High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. 
  • High yield reproducible rat model recapitulating human Barrett's carcinogenesis. 
  • Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. 
  • Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. 
  • Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. 
  • IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. 
  • Identification and functional characterization of JWA polymorphisms and their association with risk of gastric cancer and esophageal squamous cell carcinoma in a Chinese population. 
  • Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. 
  • Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer. 
  • Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer. 
  • Impact of Time to Endoscopic Resection on Outcomes for Stage I Esophageal Adenocarcinoma. 
  • Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. 
  • Improving outcomes after esophagectomy: the importance of preventing postoperative pneumonia. 
  • In situ detection of neoplastic transformation and chemopreventive effects in rat esophagus epithelium using angle-resolved low-coherence interferometry. 
  • In situ nuclear morphology measurements using light scattering as biomarkers of neoplastic change in animal models of carcinogenesis. 
  • In vivo cancer diagnosis of the esophagus using differential normalized fluorescence (DNF) indices. 
  • In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. 
  • Incidental Squamous Cell Carcinoma In Situ in a Large Pharyngoesophageal (Zenker's) Diverticulum. 
  • Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 
  • Integrated genomic characterization of oesophageal carcinoma. 
  • Intramural esophageal hamartoma: a report of two cases and review of the literature. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy. 
  • Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer. 
  • Irrational exuberance in clinical proteomics. 
  • Is There a Role for Surgery in Patients with Neuroendocrine Tumors of the Esophagus? A Contemporary View from the NCDB. 
  • Isolated primary non-hodgkin's lymphoma of the esophagus. 
  • It's not always too late: a case for minimally invasive salvage esophagectomy. 
  • LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia. 
  • Laser-induced fluorescence for esophageal cancer and dysplasia diagnosis. 
  • Laser-induced fluorescence spectroscopy: somewhere over the rainbow. 
  • Leiomyosarcoma of the esophagus. Report of two cases, one with associated squamous cell carcinoma. 
  • Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. 
  • Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. 
  • Malignant melanoma metastatic to the gastrointestinal tract. 
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. 
  • Measuring the quality of Barrett's esophagus management with measures that are high quality. 
  • Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. 
  • MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer. 
  • MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model. 
  • Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Comparison of Early Surgical Outcomes From The Society of Thoracic Surgeons National Database. 
  • Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Population-Based Analysis. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • Molecular and genetic markers in thoracic surgery. 
  • Molecular biologic staging of esophageal cancer. 
  • Molecular biology of esophageal cancer. 
  • Molecular staging of lung and esophageal cancer. 
  • Mortality among autoworkers manufacturing electronics in Huntsville, Alabama. 
  • Mucoepidermoid carcinoma of the esophagus: a case report. 
  • Multi-institutional Care in Clinical Stage II and III Esophageal Cancer. 
  • New 3-Tiered Circumferential Resection Margin Criteria in Esophageal Squamous Cell Carcinoma. 
  • Nuclear morphology measurements with angle-resolved low coherence interferometry for application to cell biology and early cancer detection. 
  • Obesity and esophagectomy for esophageal cancer: is it only the high BMI that defines prognosis? 
  • Ocular metastasis as the initial presentation of esophageal carcinoma. 
  • Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. 
  • Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. 
  • Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study. 
  • Outcomes of tracheobronchial stents in patients with malignant airway disease. 
  • Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. 
  • Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. 
  • Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. 
  • PAX9 regulates squamous cell differentiation and carcinogenesis in the oro-oesophageal epithelium. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer. 
  • PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. 
  • Pathogenesis and Cells of Origin of Barrett's Esophagus. 
  • Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. 
  • Patterns of Care in Neoadjuvant Chemoradiotherapy for Node-Positive Esophageal Adenocarcinoma. 
  • Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer. 
  • Patterns of care study decision tree and management guidelines for esophageal cancer. American College of Radiology. 
  • Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990. 
  • Patterns of recurrence after trimodality therapy for esophageal cancer. 
  • Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. 
  • Personalized and targeted therapy of esophageal squamous cell carcinoma: an update. 
  • Personalized targeted therapy for esophageal squamous cell carcinoma. 
  • Pharyngoesophageal reconstruction using free jejunal interposition grafts. 
  • Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial. 
  • Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. 
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 
  • Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. 
  • Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. 
  • Plasmonic nanobiosensors for detection of microRNA cancer biomarkers in clinical samples. 
  • Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. 
  • Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations. 
  • Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population. 
  • Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations. 
  • Polypoid tumor of the esophagus. 
  • Postoperative function of "free" jejunal transplants for replacement of the cervical esophagus. 
  • Potentially functional genetic variants of the notch signaling pathway genes predict survival of Chinese patients with esophageal squamous cell carcinoma. 
  • Potentially functional polymorphisms in the ERCC2 gene and risk of esophageal squamous cell carcinoma in Chinese populations. 
  • Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. 
  • Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma. 
  • Predictors of Major Morbidity or Mortality After Resection for Esophageal Cancer: A Society of Thoracic Surgeons General Thoracic Surgery Database Risk Adjustment Model. 
  • Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. 
  • Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. 
  • Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). 
  • Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. 
  • Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. 
  • Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. 
  • Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. 
  • Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. 
  • Primary malignant melanoma of the esophagus. 
  • Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma. 
  • Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers. 
  • Prior tonsillectomy is associated with an increased risk of esophageal adenocarcinoma. 
  • Prognostic factors affecting mortality in patients with esophageal GISTs. 
  • Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. 
  • Prospective grading of neoplastic change in rat esophagus epithelium using angle-resolved low-coherence interferometry. 
  • Pseudosarcoma of the esophagus. 
  • Pseudosarcoma of the esophagus: barium swallow and CT findings. 
  • Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations. 
  • Quality of life in patients with Barrett's esophagus undergoing surveillance. 
  • RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. 
  • Radiation and chemotherapy in the treatment of esophageal cancer. 
  • Radiation dose escalation in combined-modality therapy for esophageal cancer. 
  • Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. 
  • Reducing hospital morbidity and mortality following esophagectomy. 
  • Reply to Moris et al. 
  • Reply: To PMID 23063200. 
  • Resection of the irradiated esophagus: the impact of lymph node yield on survival. 
  • Results of the FFCD 9901 trial in early-stage esophageal carcinoma: is it really about neoadjuvant therapy? 
  • Revascularized jejunal graft replacing the cervical esophagus: radiographic evaluation. 
  • Robotic Esophagectomy Trends and Early Surgical Outcomes: The US Experience. 
  • SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. 
  • Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. 
  • Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development. 
  • Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. 
  • Short-term outcomes after esophagectomy at 164 American College of Surgeons National Surgical Quality Improvement Program hospitals: effect of operative approach and hospital-level variation. 
  • Small-bowel malabsorption and gastrointestinal malignancy. 
  • Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. 
  • Socioeconomic Status, Not Race, Is Associated With Reduced Survival in Esophagectomy Patients. 
  • Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Spectroscopic diagnosis of esophageal cancer: new classification model, improved measurement system. 
  • Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. 
  • Staging of esophageal cancer by EUS: staging accuracy revisited. 
  • Study of Spinal Cord Substructure Expansion Margin in Esophageal Cancer. 
  • Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. 
  • Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. 
  • Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? 
  • Surgical treatment of malignant esophageal tumors in PUMC Hospital. 
  • Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. 
  • Sweet's syndrome with neurologic manifestations in a patient with esophageal adenocarcinoma: case report and review of the literature. 
  • Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 
  • Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. 
  • Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. 
  • Technical considerations in radiation therapy for gastroesophageal junction cancer. 
  • The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. 
  • The Comparison of Surgical Approaches in Locally Advanced Esophageal Cancer: Significant Insights but Clinical Fidelity Still to Be Delivered. 
  • The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. 
  • The Effect of Timing of Adjuvant Therapy on Survival After Esophagectomy. 
  • The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia. 
  • The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. 
  • The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer. 
  • The Relationship Between Lymph Node Ratio and Survival Benefit With Adjuvant Chemotherapy in Node-positive Esophageal Adenocarcinoma. 
  • The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. 
  • The Society of Thoracic Surgeons Composite Score for Evaluating Esophagectomy for Esophageal Cancer. 
  • The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. 
  • The association between genetically elevated polyunsaturated fatty acids and risk of cancer. 
  • The current treatment of achalasia. 
  • The effect of age on survival after endoscopic resection versus surgery for T1a esophageal cancer. 
  • The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study. 
  • The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 
  • The impact of cirrhosis on esophageal cancer surgery: An up-to-date meta-analysis. 
  • The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. 
  • The oncogenomic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3. 
  • The prognostic importance of the number of dissected lymph nodes after induction chemoradiotherapy for esophageal cancer. 
  • The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. 
  • The role of individualized treatment in patients with oesophageal cancer: mind the patient and not only the disease. 
  • The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. 
  • The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature. 
  • The yield and the predictors of esophageal pathology when upper endoscopy is used for the initial evaluation of dysphagia. 
  • Tissue self-affinity and polarized light scattering in the born approximation: a new model for precancer detection. 
  • Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. 
  • Transhiatal esophagogastrectomy for an isolated ovarian cancer metastasis to the esophagus. 
  • Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients. 
  • Traveling to a High-volume Center is Associated With Improved Survival for Patients With Esophageal Cancer. 
  • Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. 
  • Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. 
  • Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. 
  • Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. 
  • Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. 
  • Tumor marker expression is predictive of survival in patients with esophageal cancer. 
  • Underlying mechanisms of change in cancer prevalence in older U.S. adults: contributions of incidence, survival, and ascertainment at early stages. 
  • Utilization Trends and Volume-outcomes Relationship of Endoscopic Resection for Early Stage Esophageal Cancer. 
  • Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. 
  • [Surgical treatment of malignant esophageal tumors in PUMC Hospital]. 
  • miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. 
• 

  Keywords of People

  • Garman, Katherine Schuver, Associate Professor of Medicine, Medicine, Gastroenterology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Wax, Adam P., Professor of Biomedical Engineering, Biomedical Engineering